Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
BILLERICA, Mass.--(BUSINESS WIRE)--May 22, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. Quanterix's presentation is scheduled for Wednesday, May 29, 2024, at 11:40 a.m. ET. The fireside chat will be made available to attendees and to the public via webcast.
馬薩諸塞州比利裏卡——2024年5月22日——Quanterix公司（納斯達克：quanterix）是一家通過超靈敏生物標誌物檢測推動科學發現的公司，今天宣佈首席執行官Masoud Toloue將在2024年Leerink Partners Healthcare Crossroads Conference上進行火爐暢談。Quanterix的演講定於2024年5月29日星期三美國東部時間上午11:40舉行。屆時，會議現場和公衆可以通過網絡直播觀看該活動。
Webcast Information
The live webcast of Quanterix's presentation can be accessed here, and from the Investor section of the company' website at www.Quanterix.com. Replays of the presentation will be available for a limited time following the conference.
網絡直播信息
Quanterix的演示現場可以通過以下方式進行實時觀看這裏，也可以從公司網站的投資者部分www.Quanterix.com進行視頻回放，回放時間在會議結束後有限。
To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix's Simoa technology, visit: www.quanterix.com/simoa-technology/.
要了解更多有關Quanterix的信息，請訪問www.quanterix.com/about。要了解Quanterix的Simoa技術，可訪問：www.quanterix.com/simoa-technology/。.
About Quanterix
From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
關於Quanterix
從探索到診斷，Quanterix的超敏生物標記物檢測通過其無與倫比的靈敏度和適應性推動了突破。該公司的Simoa技術提供了血液、血清或血漿中更早期生物標誌物檢測的黃金標準，能夠量化遠低於檢測限（LoQ）的蛋白質。其行業領先的精密儀器、數字免疫測定技術和CLIA認證的Accelerator實驗室支持了神經學、腫瘤學、免疫學、心臟病學和傳染病領域的疾病認知和管理的研究。Quanterix已成爲科學界近20年的可靠合作伙伴，支持在2900多個同行評審期刊上發表的研究。在位於馬薩諸塞州比勒利卡的該公司網站上查找有關該公司的其他信息https://www.quanterix.com或關注我們的推特和頁面。LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522008584/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240522008584/en/
Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
媒體聯繫人：
PAN通訊
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations Contact:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com
投資者關係聯繫方式：
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com
Source: Quanterix Corporation
來源：quanterix公司